Clinical Development Director
Didier Saurigny is Clinical Development Director in ImmunoInflammation at GSK. He has nearly 20 years of experience in the pharmaceutical industry, with leadership positions in Novartis, Roche/Genentech, MedImmune and Takeda and roles spanning all phases of clinical development. Didier joined GSK in 2017 from Takeda where he was Clinical lead in Rheumatoid Arthritis. Didier has a broad clinical development background in Immunology in particular Rheumatoid Arthritis and Juvenile Idiopathic Arthritis but also in Oncology, CVGI and Drug Safety.
Didier has a proven track record on delivering successfully complex global (>30 countries in every continent) clinical development program in phase 2a, 2b and 3. He has been instrumental in approvals of a RA compound both in the USA (BLA, sBLA) and Europe (First Approval, Type 2 variation) on the back of successfully led trials. This is a personal account. I am only sharing my opinion and not speaking on behalf of any company.